Erectile Dysfunction and Ejaculatory Dysfunction in Covid-19 Recovered Patient: Temporary or Persistent?
Urology Journal,
Vol. 22 No. 02 (2025),
2 March 2025
,
Page 102-105
https://doi.org/10.22037/uj.v21i.8113
Abstract
Purpose: Examine the prevalence of erectile dysfunction and ejaculatory dysfunction among COVID-19 recovered patients and whether this condition improved over time. The retrospective study of 50 male patients who have recovered from COVID-19 infection previously hospitalized in dr. H Abdul Moeloek General Hospital between March 2020 – March 2021.
Materials and Methods: All of these patients were evaluated in terms of erectile and ejaculation function via phone interview. The International Index of Erectile Function 5 (IIEF-5) and Male sexual health questionnaire ejaculatory dysfunction (MHSQ-EJD) were used to assess the erectile function and ejaculatory dysfunction. Statistical analysis was performed to evaluate whether there was a difference between IIEF-5 & MHSQ-EJD scores within 6 months, 6 to 12 months, and >24 months after COVID-19 infection.
Results: The prevalence of ED was 70% and EJD was 2 % during 0-6 months after COVID-19 infection. Mean age and BMI were 50.4 ± 8.5 years and 23.6 ± 1.6 kg/m2 respectively. There are 26 patients (52%) had an educational background lower than bachelor’s degree and 24 patients (48%) had an educational background of bachelor’s degree or higher. It was reported that 4 patients (8%) had Diabetes Mellitus and 12 patients (24%) had Hypertension. Most were active smokers (74%) and 2 patients (4%) had reported as active alcohol drinkers. There was a statistically significant IIEF-5 scores difference between three periods of time (p <0,001).
Conclusion: The prevalence of Erectile Dysfunction was high in COVID-19 recovered patients. There was a temporary erectile dysfunction and ejaculatory dysfunction among COVID-19 patients.
- erectile dysfunction
- ejaculatory dysfunction
- covid-19
How to Cite
References
Söksüz M, Kiliç S, Saraç F. Coronaviruses and SARS-COV-2. Turk J Med Sci 2020;50:549-56.
World Health Organization. Update on COVID-19 October 2023. Available online: https://covid19.who.int/.
Abobaker A, Raba AA, Alzwi A. Extrapulmonary and atypical clinical presentations of COVID‐19. J Med Virol. 2020;92:2458-64.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-80.
Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: Issues affecting the results. Expert Rev Mol Diagn. 2020;20:453–4.
NIH Consensus Development Panel on Impotence. NIH Consensus Conference: impotence. JAMA. 1993;270:83-90.
Lue TF. Erectile dysfunction. N Engl J Med. 2000; 15:1802-13.
Kessler A, Sollie S, Challacombe B, Briggs K, Van Hemelrijck M. The global prevalence of erectile dysfunction: a review. BJU Int. 2019;124:587-99.
Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int. 2005;96:1339-1354
Birowo P, Deswanto IA, Rasyid N. Epidemiology of erectile dysfunction: A cross-sectional web-based survey conducted in an Indonesian national referral hospital. F1000Research. 2019 ; 7 :817-817.
Zhang J, Shi W, Zou M, et al. Prevalence and risk factors of erectile dysfunction in COVID-19 patients: a systematic review and meta-analysis. J Endocrinol Invest. 2023;46:795-804.
Katz J, Yue S, Xue W, Gao H. Increased odds ratio for erectile dysfunction in COVID-19 patients. J Endocrinol Invest. 2022;45:859-64.
Harirugsakul K, Wainipitapong S, Phannajit J, Paitoonpong L, Tantiwongse K. Erectile dysfunction after COVID-19 recovery: A follow-up study. Plos one. 2022; 20:1-12
J Kahn M, H Maley J, F Lasker G, J Kadowitz P. Updated role of nitric oxide in disorders of erythrocyte function. Cardiovascular & Haematological Disorders-Drug Targets (Formerly Current Drug Targets-Cardiovascular & Hematological Disorders). 2013;13:83-7.
Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020 ; 1 :9-14.
Loot AE, Schreiber JG, Fisslthaler B, Fleming I. Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase. J Exp Med. 2009; 21:2889-96.
Akhigbe RE, Hamed MA. Possible links between COVID-19 and male fertility. Asian Pac. J. Reprod. 2020; 1:211-4.
A.M Rabie. Covid 19 and sexual dysfunction in men : SARS-COV 2 in the testes. Sexologies .2021; 30:141-148
Behtash N, Karimi Babaahmadi A. Erectile Dysfunction in Hospitalized Men with COVID-19. Transl Res Urol. 2022; 1: 141-4.
Gök A, Altan M, Doğan AE, et al. Does Post-COVID-19 Erectile Dysfunction Improve over Time?. J. Clin. Med. 2023; 3:1241.
Kumar V, Kaur M. COVID-19 Vaccine and Male Fertility. Urolj. 2023 ; 20 : 278-279.
Kashi AH. COVID-19 and Semen: An Unanswered Area of Research. Urolj. 2020;17:328
- Abstract Viewed: 640 times
- 8113/pdf Downloaded: 391 times